Argenx

Navigating the AI 'hype cycle': Bayer, Daiichi Sankyo and argenx leaders on implementing AI in biopharma marketing
Fierce Pharma
Thu, 09/19/24 - 11:06 am
artificial intelligence
Bayer
Daiichi Sankyo
Argenx
J&J unwraps pivotal data on $6.5B autoimmune asset as it prepares to crash argenx and UCB's party
Fierce Biotech
Mon, 07/1/24 - 11:23 am
JNJ
nipocalimab
myasthenia gravis
clinical trials
UCB
Argenx
Argenx shrugs off myasthenia gravis threat from UCB as Vyvgart nears next potential launch
Fierce Pharma
Fri, 05/10/24 - 11:37 am
Argenx
myasthenia gravis
Vyvgart
FDA starts review of Argenx drug in rare disease CIDP
Pharmaphorum
Tue, 02/20/24 - 11:01 am
Argenx
Vygart Hytrulo
CIDP
FDA
Argenx dealt another blow as Vyvgart Hytrulo fails again
Pharmaphorum
Wed, 12/20/23 - 09:28 am
Argenx
Vyvgart
clinical trials
Vyvgart Hytrulo
pemphigus vulgaris
On blockbuster path, Argenx's red-hot Vyvgart comes up short in thrombocytopenia trial
Fierce Pharma
Wed, 11/29/23 - 12:02 pm
Argenx
Vyvgart
thrombocytopenia
clinical trials
Argenx's Vyvgart gains commercial momentum in gMG as company plots expansion into new uses
Fierce Pharma
Wed, 11/1/23 - 11:04 am
Argenx
Vygart
myasthenia gravis
Vyvgart shines in CIDP study, teeing up another potential nod for Argenx's pipeline in a product
Fierce Pharma
Tue, 07/18/23 - 10:29 am
Argenx
Vyvgart
clinical trials
CIDP
Unpartnered assets: on the shelf or hidden treasure?
EP Vantage
Thu, 06/15/23 - 09:54 am
R&D
ALX Oncology
Argenx
Ascendis Pharma
Cytokinetics
Karuna Therapeutics
Madrigal Pharmaceuticals
Protagonist Therapeutics
Prothena
Ultragenyx Pharmaceutical
Unique Pharma
Ventyx Biosciences
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
Wed, 05/31/23 - 10:51 am
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Argenx, Genmab pool expertise on antibody discovery, joining forces to expand into new therapeutic areas
Fierce Biotech
Mon, 04/17/23 - 11:19 am
Genmab
Argenx
antibody discovery
drug discovery
cancer
immunology
OncoVerity eyes cusatuzumab development in AML after licensing rights
Pharmaceutical Technology
Tue, 03/28/23 - 10:41 pm
OncoVerity
Argenx
AML
cusatuzumab
Biotech heads towards big catalysts
EP Vantage
Tue, 03/28/23 - 10:24 am
biotech
clinical trials
Alnylam Pharmaceuticals
Arcus Biosciences
Argenx
Arrowhead Pharmaceuticals
Axsome Therapeutics
Bavarian Nordic
FibroGen
Gilead Sciences
Incyte
Morphic Therapeutic
PTC Therapeutics
Syndax Pharmaceuticals
Travere Therapeutics
Vaxcyte
The world needs Garp, according to Abbvie
EP Vantage
Fri, 02/10/23 - 10:20 am
AbbVie
GARP
Argenx
R&D
Biotech’s key upcoming clinical results
EP Vantage
Tue, 12/20/22 - 10:27 am
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
BioPharma Dive
Mon, 12/12/22 - 10:56 pm
ASH 2022
JNJ
talquetamab
Multiple Myeloma
Argenx
Bluebird Bio
Vyvgart
ITP
ASH: With immune thrombocytopenia win, argenx proves efgartigimod's no one-trick pony in autoimmune disease
Fierce Pharma
Sun, 12/11/22 - 01:32 pm
ASH 2022
ITP
efgartigimod
Argenx
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
Benzinga
Wed, 11/30/22 - 10:47 am
Bluebird Bio
priority review vouchers
FDA
Argenx
Argenx Scores Priority Review for Generalized Myasthenia Gravis Therapeutic
BioSpace
Tue, 11/22/22 - 04:30 pm
Argenx
FDA
priority reviews
myasthenia gravis
efgartigimod
Seeking sibling for Vyvgart, argenx files for FDA approval of subcutaneous efgartigimod
Fierce Pharma
Tue, 09/27/22 - 10:16 am
Argenx
Vyvgart
myasthenia gravis
efgartigimod
FDA

Pages